Alzheimer's Disease Trial, Recruiting NCT07099053 Sponsor: National Institute on Aging (NIA) Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT07099053
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 55 years or older who are already part of an existing long-term research study called the Baltimore Longitudinal Study of Aging (BLSA)
  • People who have already had an MRI scan as part of the BLSA study, or who have agreed to have one
  • People who are able to understand and agree to participate in the study on their own (the ability to give consent is assessed as part of the regular BLSA visit)

Who may not be able to join:

  • People younger than 55 years of age
  • People who are pregnant
  • People who have a pre-existing disease of the brain or central nervous system (the brain and spinal cord)
  • People who weigh more than 300 lbs
  • People with active cancer that has spread to other parts of the body (skin cancer of the basal cell type is an exception)
  • People with a pacemaker or any implanted electronic hearing device
  • People who have had breast cancer treated with radiation
  • People who have lymphoma (a type of blood cancer)
  • People who have a brain tumour
  • People who have metal shrapnel in their body
  • People with schizophrenia
  • People with bipolar disorder
  • People with epilepsy
  • People who have a language barrier that makes communication during the study difficult
  • People with a brain aneurysm larger than 3mm, or who have aneurysm clips (small metal devices used to treat aneurysms)
  • People with Parkinson's disease, or who take medications used to treat Parkinson's disease
  • People with Huntington's disease
  • People with poorly controlled diabetes (specifically, a blood sugar measurement called HbA1c above 8); treated and well-controlled diabetes is generally acceptable (confirm with trial site)
  • People with severe hormonal or gland-related conditions; treated thyroid conditions are generally acceptable (confirm with trial site)
  • People who have been diagnosed with dementia or mild cognitive impairment
  • People who are not eligible to have an MRI scan for any reason
  • People who have had a stroke, or who have had a series of small strokes (called TIAs) that required a hospital stay
  • People with known abnormal blood vessels or certain types of growths in the brain
  • People with a history of significant exposure to radiation
  • People who score 4 or higher on a memory and thinking assessment used within the BLSA will need to be reviewed by a research panel to rule out dementia before a decision on participation is made

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Luigi Ferrucci, M.D., National Institute on Aging (NIA)

Phone: (410) 558-8610

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
National Institute on Aging (NIA)
Registry
ClinicalTrials.gov
Start date
28 July 2026
Est. completion
12 December 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Amyloid accumulation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov